Related Experiment Video

Updated: Mar 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

[Immune Checkpoint for a Kidney Cancer and Other Cancers]

Shunichiro Kageyama1, Shigeo Yamaguchi, Kayo Miura

  • 1Dept. of Medical Oncology, Juntendo University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 17, 2016
PubMed

Insights

Immune checkpoint inhibitors show promise in cancer treatment, with nivolumab improving survival in kidney and head and neck cancers. Further trials are expanding their use, but challenges remain.

Area of Science:

  • Oncology
  • Immunology

Context:

  • Immune checkpoint inhibitors are gaining traction in cancer therapy.
  • Clinical trials initially focused on melanoma and lung cancer.
  • Expansion to other cancer types is underway, with 31 phase III trials for 13 cancers completed.

Purpose:

  • To review clinical trial trends for immune checkpoint inhibitors.
  • To discuss future prospects and challenges in their application.
  • To highlight recent trial results and expected approvals.

Summary:

  • Nivolumab demonstrated improved overall survival in kidney and head and neck cancers compared to existing treatments.
  • Recent trial results (CheckMate025, CheckMate141) support nivolumab's efficacy.
  • Broader approval for nivolumab in renal cell and head and neck cancers is anticipated.

Impact:

  • Upcoming phase III trial results (2017-2019) are expected to expand approvals.
  • Key challenges include biomarker identification, efficacy assessment, and economic impact.
  • This research provides insights into the evolving landscape of immune checkpoint inhibitor therapy.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
455